Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Barclays Maintains Equal-Weight on Texas Instruments, Raises Price Target to $165

Barclays Maintains Equal-Weight on Texas Instruments, Raises Price Target to $165

Barclays analyst Blayne Curtis maintains Texas Instruments (NASDAQ:TXN) with a Equal-Weight and raises the price target from $150 to $165.

byBenzinga Newsdesk

January 23, 2023

1 minute read

Barclays analyst Blayne Curtis maintains Texas Instruments (NASDAQ:TXN) with a Equal-Weight and raises the price target from $150 to $165.

Snap’s Meta Move: Swiping Ad Gurus to Revitalize Its Ad Strategy

By Anusuya Lahiri

May 1, 2:48 PM

Snap Inc (NYSE:SNAP) roped in two former Meta Platforms, Inc (NASDAQ:META) employees to expand its advertising business. Snap appointed Patrick Harris to the…

AAPL

Luxair Announces Purchase Of Two Boeing 737-8

By Bill Haddad

March 3, 8:34 AM

-Reuters

Analyst Ratings

18 Analysts Have This To Say About Crinetics Pharmaceuticals

By Benzinga Insights

May 14, 12:00 PM

In the last three months, 18 analysts have published ratings on Crinetics Pharmaceuticals (NASDAQ:CRNX), offering a diverse range…

CRNX

Aleafia Health FY23 Revenue Stagnates, What About Profit?

By Vuk Zdinjak

June 14, 10:45 AM

Aleafia Health Inc. (OTCQB: ALEAF) (TSX:AH) released its audited financial results for the three and twelve months ended March 31, 2023, revealing net revenue of CA$42.8 million ($32.2 million), a decrease of 0.6% compared to CA$43.1 million in FY 2022.

ALEAF

Barclays Maintains Equal-Weight on Texas Instruments, Raises Price Target to $165

Related Posts

Snap’s Meta Move: Swiping Ad Gurus to Revitalize Its Ad Strategy

Luxair Announces Purchase Of Two Boeing 737-8

18 Analysts Have This To Say About Crinetics Pharmaceuticals

Aleafia Health FY23 Revenue Stagnates, What About Profit?